Affimed's product pipeline includes candidates with a high market potential in the indications of oncology, thrombosis and auto-immune diseases. Currently, several products are in an advanced preclinical stage, while additional, new antibody leads have been isolated for major cancer indications. Affimed's lead programs are TandAbs for the treatment of Non-Hodgkin's Lymphoma (AFM11 and AFM12) and Hodgkin's Disease (AFM13). These lead programs address validated targets for these diseases that are particularly amenable to the TandAb format. Additional preclinical programs address Thrombosis (AFM14) and Autoimmune Disease (AFM15).
Affimed's product pipeline
Affimed also has a number of discovery programs in Leukaemia, Myeloma, solid tumors, metastasis and Non-Hodgkin's Lymphoma as well as non-cancer indications such as Autoimmune Disease, Allergy and Asthma:
